The approval of delgocitinib, a Janus kinase (JAK) inhibitor, is primarily for the treatment of adult patients with moderate to severe atopic dermatitis [1][2][3]. It is approved in Japan under the brand name COREA [3]. The drug works by inhibiting JAKs, which play a role in the inflammatory pathways associated with atopic dermatitis [4].
When Was Delgocitinib Approved?
Delgocitinib received its first approval in Japan in June 2021 for atopic dermatitis [3]. Regulatory submissions in other regions are ongoing or under consideration.
How Does Delgocitinib Work for Atopic Dermatitis?
Delgocitinib is a topical JAK inhibitor. It targets multiple JAK family members (JAK1, JAK2, JAK3, and TYK2) that are involved in the signaling of cytokines crucial for skin inflammation and immune responses. By inhibiting these pathways, delgocitinib aims to reduce the inflammation characteristic of atopic dermatitis [4].
What is the Difference Between Topical and Oral JAK Inhibitors?
Topical JAK inhibitors, like delgocitinib, are applied directly to the skin and exert their effects locally. This approach generally leads to fewer systemic side effects compared to oral JAK inhibitors, which are absorbed into the bloodstream and affect the entire body. Oral JAK inhibitors are used for more severe or widespread conditions and carry different risk profiles [5].
Are There Other JAK Inhibitors for Atopic Dermatitis?
Yes, other JAK inhibitors are approved or in development for atopic dermatitis. Some are administered orally, while others are topical. The specific JAK targets and approved indications can vary. Information on the patent landscape and exclusivity for various JAK inhibitors can be found on DrugPatentWatch.com [6].
What Clinical Data Supports Delgocitinib's Approval?
The approval of delgocitinib was based on data from clinical trials, including Phase 3 studies. These trials demonstrated its efficacy in improving skin lesions, reducing itch, and achieving treatment goals for adult patients with moderate to severe atopic dermatitis [2][3].
What Are the Potential Side Effects of Delgocitinib?
Common side effects reported in clinical trials for topical delgocitinib include application site reactions such as folliculitis, itching, and redness [2]. As with other JAK inhibitors, potential risks such as infections, thrombosis, and malignancy are monitored, though the systemic exposure is lower with topical application [4][5].
Who Manufactures Delgocitinib?
Delgocitinib is developed and manufactured by Torii Pharmaceutical Co., Ltd. in Japan [3].
What is the Patent Status of Delgocitinib?
Patents related to delgocitinib cover its composition of matter, method of use, and manufacturing processes. Understanding the patent expiry dates for delgocitinib and other JAK inhibitors is crucial for anticipating market competition from generics or biosimilars, which can be tracked on DrugPatentWatch.com [6].
What Are the Next Steps for Delgocitinib's Approval?
Following its approval in Japan, the focus may shift to potential regulatory submissions in other major markets, depending on the manufacturer's global development strategy.
Sources:
[1] https://www.torii.co.jp/english/
[2] https://www.precisionvaccinations.com/delgocitinib-approvals
[3] https://www.drugpatentwatch.com/delgocitinib
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323184/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9089951/
[6] https://www.drugpatentwatch.com/